Eur J Pharm Sci:色苷酸交联壳聚糖纳米粒子治疗过敏性鼻炎的效果研究

2019-03-03 AlexYang MedSci原创

最近,有研究人员开发了粘膜粘着鼻血管收缩纳米粒子药物,具体是直接通过阳离子聚合物壳聚糖和阴离子药物色苷酸的交联来获得。研究人员利用不同的壳聚糖/色苷酸摩尔比来获得合适大小、包装效率/药物装载好和粘膜粘附能力好的纳米颗粒。更多的是,研究人员评估了纳米粒子传输色甘酸到鼻粘膜的能力。研究发现,获得的带正电纳米粒子且大小为180nm-400nm时,表现出让人感兴趣的产量、粘膜粘着能力和包装能力和药物装载能

最近,有研究人员开发了粘膜粘着鼻血管收缩纳米粒子药物,具体是直接通过阳离子聚合物壳聚糖和阴离子药物色苷酸的交联来获得。研究人员利用不同的壳聚糖/色苷酸摩尔比来获得合适大小、包装效率/药物装载好和粘膜粘附能力好的纳米颗粒。更多的是,研究人员评估了纳米粒子传输色甘酸到鼻粘膜的能力。

研究发现,获得的带正电纳米粒子且大小为180nm-400nm时,表现出让人感兴趣的产量、粘膜粘着能力和包装能力和药物装载能力。药物释放和渗透能力表明了纳米粒子能够将大量的色甘酸传送到鼻粘膜中,并且在肥大细胞中富集。最后,研究人员指出,他们的发现表明了发展血管收缩纳米颗粒治疗药物具有治疗过敏性鼻炎的潜力。

原始出处:

Abruzzo A, Cerchiara T, Bigucci F et al. Cromolyn-crosslinked chitosan nanoparticles for the treatment of allergic rhinitis. Eur J Pharm Sci. 13 Feb 2019.

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-04-21 1254a331m32暂无昵称

    有些无厘头的感觉

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-03-07 1df0e68am86(暂无匿称)

    加油(???_??)?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-03-03 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1787594, encodeId=bf521e87594a5, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 21 22:15:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047085, encodeId=58c0204e085cc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 26 01:15:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772980, encodeId=3c101e7298021, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Tue Aug 06 11:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365024, encodeId=148a365024b6, content=有些无厘头的感觉, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43502553928, createdName=1254a331m32暂无昵称, createdTime=Sun Apr 21 10:10:53 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362194, encodeId=dd2d3621948f, content=加油(???_??)?, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f6b1741627, createdName=1df0e68am86(暂无匿称), createdTime=Thu Mar 07 14:39:19 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580655, encodeId=aefe1580655b8, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582429, encodeId=4bf015824294a, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f716920725, createdName=dlwang_26703132, createdTime=Tue Mar 05 03:15:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046766, encodeId=05121046e66bd, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 03 15:15:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361904, encodeId=6e2a3619046b, content=。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c2c79604, createdName=pepsitjw, createdTime=Sun Mar 03 12:23:52 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-03-03 pepsitjw

    。。。。。

    0

相关威廉亚洲官网

Clin Exp Allergy:无症状HDM敏感和HDM过敏性鼻炎患者的临床和免疫学差异

对敏感症的临床相关性确定对过敏性鼻炎的诊断非常重要。最近,有研究人员调查了体外嗜碱性细胞活化试验和溶解组分诊断在区分症状性过敏性鼻炎患者和对室内尘螨(HDMs)无症状敏感患者中的使用价值。研究包括了66名HDM皮肤针刺试验阳性患者,并基于他们的临床历史和鼻激发测试分为症状组(n=17)和无症状组(n=19)。研究人员评估了嗜碱性CD63响应对体外过敏原屋尘螨全提取物刺激的响应和lgE对Der p

PLoS One:过敏性鼻炎儿科患者的急性鼻窦炎群体研究

虽然慢性鼻窦炎是过敏性鼻炎的常见并发症,而急性鼻窦炎与过敏性鼻炎之间的联系不清楚。最近,有研究人员利用基于群体的健康研究数据评估了患有过敏性鼻炎儿科患者的急性鼻窦炎发生率。研究包括了新诊断的年龄在5-18岁的过敏性鼻炎患者,并通过性别、年龄和年份指数匹配构建了一个比较群体。研究人员对所有的患者进行了跟踪调查,直到急性鼻窦炎诊断或者跟踪调查结束为止,并利用Cox比例风险模型评估了过敏性鼻炎和急性鼻窦

J Leukoc Biol:过敏性鼻炎患者中,白介素-5能够诱导CD4+T细胞凋亡缺陷

辅助性T细胞(Th)2极化在过敏性疾病的病理中具有重要的角色,而潜在的机制仍旧需要进一步的调查。类B细胞淋巴瘤蛋白-2蛋白12(Bcl2L12)具有抗凋亡的功能。最近,有研究人员阐释了过敏性鼻炎(AR)患者中,Bcl2L12对Th2极化的影响。研究发现,AR CD4+ T细胞(来源于AR患者)展现出了细胞凋亡的缺陷。FasL在AR CD4+ T细胞中表达要比HC(健康对照) CD4+ T细胞中更低

盘点:近期鼻疾病盘点

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。williamhill asia 医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】Rhinology:在非过敏性鼻炎中,干冷空气激发是一种可靠的诊断工具 https://www.ncbi.nlm.nih.gov/pubmed/30609423对非过敏性鼻

Pediatr Allergy Immunol:过敏性鼻炎儿童中microRNA-181a和microRNA-155参与了调节性T细胞的分化和功能调控

调控性T细胞(Tregs)在限制气道过敏性炎症和预防对环境过敏原不良Th2响应方面具有核心的作用。最近,有研究人员通过体内和体外试验评估了miR-181a和miR-155在调控Tregs分化和功能方面的作用。研究人员从过敏性鼻炎(AR)儿童的外周血单核细胞(PBMCs)中分离纯化了CD4+和Tregs,并将miR-181a/miR-155 mimics和抑制子转化CD4+和Tregs。通过流式细胞

Allergy:青少年中关于DNA甲基化和过敏性敏感的基因组纵向研究

过敏性敏感的存在对儿童常见的哮喘和鼻炎的发展具有重要的影响。过敏性敏感的病因仍旧不清楚,并且其潜在的机制还没有建立。一些研究表明一些CpGs的DNA甲基化(DNAm)与过敏性敏感相关。然而,尚没有研究关注青少年时期。最近,有研究人员使用线性混合模型评估了青春期前后全基因组DNAm与室内、室外和食物过敏原过敏敏感之间相关性。研究发现,通过线性混合模型,鉴定了35个CpGs与过敏性敏感相关(错误发现率